In-Stock Drugs of the market serve as initial assistance for Coronavirus affected patients

Amidst the coronavirus outbreak, every country is worried about the vaccination. The toll has touched 80,000 for coronavirus infected cases. As the number is rising day by day, countermeasures should be taken to cure this pandemic, so first-hand prophylaxis is of utmost importance to stabilize the patient for further treatment.

Though a European group of scientists is claiming that there approved drugs might treat the virus but their findings are considered not more than a pre-proof by the International Journal of Infectious Diseases.

Denis Kainov, the senior author and an associate professor at the Norwegian University of Science and Technology (NTNU) told, “Drug repurposing is a strategy for generating additional value from an existing drug by targeting diseases other than that for which it was originally intended, For example, teicoplanin, oritavancin, dalbavancin, and monensin are approved antibiotics that have been shown to inhibit corona- and other viruses in the laboratory.”

In addition to this, Kainov and his co-authors agreed that as currently there are no hardcore medicines for COVID-19 by WHO so these antiviral drugs can be of help for first stage diagnosis. The WHO claimed the virus “can cause mild symptoms including a runny nose, sore throat, cough, and fever. It can be more severe for some persons and can lead to pneumonia or breathing difficulties. More rarely, the disease can be fatal. Older people and people with pre-existing medical conditions (such as diabetes and heart disease) appear to be more vulnerable to becoming severely ill with the virus.”

The repurposing of the drug is based on chemical synthesis and manufacturing processes with different phases of clinical testing. The researcher’s findings said,” Therefore, repositioning of launched or even failed drugs to viral diseases provides unique translational opportunities, including a substantially higher probability of success to market as compared with developing new virus-specific drugs and vaccines, and a significantly reduced cost and timeline to clinical availability.”

The analysis of broad-spectrum antiviral drugs accords that they target viruses from several families of viruses. Among 120 drugs that were found to be safe for human usage, 31 drugs were found to treat COVID 19 virus.

The conclusion by researchers was, “In the future, BSAAs will have a global impact by decreasing morbidity and mortality from viral and other diseases, maximizing the number of healthy life years, improving the quality of life of infected patients and decreasing the costs of patient care.”